bendamustine hydrochloride has been researched along with Hematologic Diseases in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abramson, JS; Barr, PM; Bartlett, NL; Blachly, JS; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Fruth, B; Heerema, NA; Hurria, A; Kuzma, C; Larson, RA; Little, RF; Litzow, M; Lozanski, G; Major-Elechi, B; Mandrekar, SJ; Nattam, S; Owen, C; Ozer, HG; Parikh, SA; Rogers, KA; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA; Zhao, W | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Avigdor, A; Aviv, A; Avivi, I; Gafter-Gvili, A; Gurion, R; Kedmi, M; Mizrahi, N; Nagler, A; Perry, C; Raanani, P; Ram, R; Ribakovsky, E; Vidal, L | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Brugger, W; Cheson, BD; Damaj, G; Dreyling, M; Kahl, B; Kimby, E; Ogura, M; Weidmann, E; Wendtner, CM; Zinzani, PL | 1 |
| Cheah, CY; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; McLaughlin, P; Nastoupil, LJ; Neelapu, SS | 1 |
| Cheson, BD; Cohen, P; Herst, JA; Lemieux, B; Robinson, KS; Schwartzberg, LS; Tulpule, A; van der Jagt, RH; Williams, ME | 1 |
| Amore, A; Angrilli, F; Arcamone, M; Califano, C; Corazzelli, G; Cox, MC; D'Arco, A; De Filippi, R; Falorio, S; Ferrara, F; Guarini, A; Iannitto, E; Musto, P; Pinto, A; Stelitano, C; Storti, S | 1 |
| Bremer, K | 1 |
| Heymanns, J; Köppler, H; Pandorf, A; Weide, R | 1 |
| Bosmans, J; Dyck, J; Merkle, K; Rasschaert, M; Schrijvers, D; Van den Brande, J; Vermorken, JB | 1 |
| Eichbaum, MH; Foerster, F; Khbeis, T; Lauschner, I; Schneeweiss, A; Schuetz, F; Sohn, C | 1 |
1 review(s) available for bendamustine hydrochloride and Hematologic Diseases
| Article | Year |
|---|---|
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consensus Development Conferences as Topic; Disease Management; Disease Progression; Drug Resistance; Hematologic Diseases; Hematologic Neoplasms; Humans; Recurrence; Retreatment | 2016 |
9 trial(s) available for bendamustine hydrochloride and Hematologic Diseases
| Article | Year |
|---|---|
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Survival Analysis | 2018 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Communicable Diseases; Hematologic Diseases; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab | 2016 |
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Gastrointestinal Diseases; Headache; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2008 |
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2002 |
Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Opportunistic Infections; Remission Induction; Survival Analysis | 2004 |
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds | 2007 |
Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Genes, erbB-2; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Nitrogen Mustard Compounds; Salvage Therapy; Survival Analysis | 2007 |
2 other study(ies) available for bendamustine hydrochloride and Hematologic Diseases
| Article | Year |
|---|---|
Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Biomarkers; Female; Hematologic Diseases; Hospitalization; Humans; Incidence; Infections; Israel; Lymphoproliferative Disorders; Male; Middle Aged; Retrospective Studies; Risk Factors | 2016 |
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle Checkpoints; Combined Modality Therapy; Disease-Free Survival; DNA Repair; Drug Evaluation; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Off-Label Use; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |